NASDAQ$GPCR
Structure Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Structure Therapeutics reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate achievements.
Structure Therapeutics reported a net loss of $26.0 million for the first quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $436.4 million as of March 31, 2024, which is expected to fund operations through at least 2026.
- Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024
- Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024
- Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in June 2024
- Cash, cash equivalents and short-term investments totaled $436.4 million on March 31, 2024.
Headline financials
Revenue & EPS history
Structure Therapeutics · Revenue · Quarterly
$0
Forward guidance
The company anticipates several milestones, including the release of Phase 2a data for GSBR-1290 in June, the initiation of a Phase 2b obesity study later in the year, and the start of a Phase 1 clinical trial for LTSE-2578 in June 2024.
Tailwinds
- Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024
- Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024
- Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in June 2024
- Advancement of the Company’s GLP-1R franchise and other research programs
- Planned timing of the Company’s data results and continued development of GSBR-1290, ANPA-0073, amylin, GIPR and next generation GLP-1R/GIPR combination candidates
Headwinds
- Risks and uncertainties related to the preliminary nature of the results due to length of the study and sample size
- The risks that unblinded data is not consistent with blinded data
- The Company’s ability to advance GSBR-1290, LTSE-2578, ANPA-0073 and its other therapeutic candidates
- The timing and results of preclinical and clinical trials
- The impact of any data collection omissions at any of our clinical sites
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2024
+1.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+9.8%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+14.8%
Q4 2024
Best reaction
-11.6%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | -2.5% | -29.1% | |
| Q3 2025 | -2.0% | +7.3% | +3.3% | |
| Q1 2025 | -4.6% | -11.2% | -21.2% | |
| Q4 2024 | +14.8% | +13.1% | -0.6% | |
| Q3 2024 | +1.9% | -14.1% | -15.5% | |
| Q2 2024 | -0.8% | +0.9% | +8.6% | |
| Q1 2024 | -8.7% | -9.0% | +35.3% | |
| Q4 2023 | -2.5% | -5.9% | +15.1% | |
| Q3 2022 | +11.5% | +7.1% | +23.4% | |
| Q3 2023 | -11.6% | -1.6% | +7.2% | |
| Q2 2023 | -1.9% | -2.9% | -0.1% | |
| Q2 2022 | -1.9% | -2.9% | -0.1% | |
| Q1 2023 | +8.9% | +1.9% | +40.2% | |
| Q4 2022 | +8.9% | +1.9% | +40.2% | |
| Q1 2022 | +8.9% | +1.9% | +40.2% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro